echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > The GV1001 drug trial yielded more positive results

    The GV1001 drug trial yielded more positive results

    • Last Update: 2021-01-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 23rd GemVax released more positive data for the GV1001 Alzheimer's II trial at the Korean Association for Theaset of Mental Disorders' autumn meeting.
    , the company has announced that the GV1001 has good tolerance and safety, and achieved the main endpoint by making significant improvements in the SIB score.
    latest data also show significant improvements in neuropsynamic scale (NPI) statistics, as well as improvements in the daily energy scale (ADCS-ADL) score for collaborative Alzheimer's research.
    these results, the company now plans to submit three IND applications.
    GemVax's GV1001 Drug Phase II clinical trial assessed the safety and effectiveness of 0.56 ml or 1.12 ml of GV1001 sepsis injections in patients with moderate to severe Alzheimer's disease who had been treated with Donai pyridox for more than three months in 12 medical institutions over a six-month period.
    note: There are deletions in the original text
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.